Drugs / CART-138/BCMA/19/more
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03196414 | Sep 2016 → Sep 2026 overdue | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-138/BCMA/19/more | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03196414 ↗ |
| Action | Deplete | “kill cancer cells” NCT03196414 ↗ |
| Modality | Cell therapy | “Genetically engineered lymphocyte (CART) therapy” NCT03196414 ↗ |
| Route | Intravenous | “The results demonstrated that BCMA-CART cells administered intravenously trafficked into the CSF, eradicated tumor cells” PMID 33717057 ↗ Feb 2021 |